ALPS Medical Breakthroughs ETF (SBIO)
| Assets | $152.33M |
| Expense Ratio | 50.00% |
| PE Ratio | n/a |
| Shares Out | 2.90M |
| Dividend (ttm) | n/a |
| Dividend Yield | n/a |
| Ex-Dividend Date | n/a |
| Payout Frequency | n/a |
| Payout Ratio | n/a |
| Volume | 26,794 |
| Open | 53.60 |
| Previous Close | 53.61 |
| Day's Range | 53.21 - 53.90 |
| 52-Week Low | 26.86 |
| 52-Week High | 57.77 |
| Beta | 0.78 |
| Holdings | 91 |
| Inception Date | Dec 31, 2014 |
About SBIO
Fund Home PageThe ALPS Medical Breakthroughs ETF (SBIO) is an exchange-traded fund that is based on the S-Network Medical Breakthroughs index. The fund tracks, a market-cap weighted index comprising US-listed biotech companies with one or more drugs currently in either Phase II or Phase III FDA clinical trials. SBIO was launched on Dec 31, 2014 and is issued by SS&C.
Top 10 Holdings
33.50% of assets| Name | Symbol | Weight |
|---|---|---|
| Kymera Therapeutics, Inc. | KYMR | 4.14% |
| Mirum Pharmaceuticals, Inc. | MIRM | 3.66% |
| Celcuity Inc. | CELC | 3.65% |
| CG Oncology, Inc. | CGON | 3.51% |
| Alkermes plc | ALKS | 3.49% |
| Spyre Therapeutics, Inc. | SYRE | 3.42% |
| Apellis Pharmaceuticals, Inc. | APLS | 3.29% |
| Xenon Pharmaceuticals Inc. | XENE | 2.93% |
| Apogee Therapeutics, Inc. | APGE | 2.84% |
| Crinetics Pharmaceuticals, Inc. | CRNX | 2.57% |
Dividend History
| Ex-Dividend | Amount | Pay Date |
|---|---|---|
| Dec 19, 2024 | $1.17346 | Dec 26, 2024 |
| Dec 21, 2023 | $0.07106 | Dec 27, 2023 |
| Dec 19, 2019 | $0.01585 | Dec 27, 2019 |
| Dec 20, 2018 | $0.7841 | Dec 27, 2018 |
| Dec 21, 2017 | $0.57949 | Dec 28, 2017 |
Performance
SBIO had a total return of 80.42% in the past year, including dividends. Since the fund's inception, the average annual return has been 7.64%.
News
Last Week's Top 5 Articles Highlight Areas of Interest, Concern
The leading articles for last week ran the gamut in terms of topics, but suggest investors are still worried about inflation and remain interested in biotech, nuclear energy, and derivatives strategie...
This Biotech ETF's Hot Start Can Continue
Broader healthcare ETFs aren't doing much to appease investors this year, but biotech funds are warding off that weakness. Just look at the ALPS Medical Breakthroughs ETF (SBIO).
UFO Takes Flight: Agility and Assets Converge in the Final Frontier
While some investment themes have struggled to maintain their trajectory, the space economy has proven it has the fundamental fuel to reach escape velocity. This momentum is being met with a strategic...
Biotech M&A Spree Helps Lead SBIO to March Gains
A surge in biotech M&A activity drove sharp gains across holdings in the ALPS Medical Breakthroughs ETF (SBIO) during March, with two of the fund's holdings becoming acquisition targets in deals worth...
Advacam & Vector Space Biosciences sign Letter of Intent (LOI) to Develop AI Models & CubeSat Payloads for the Space Industry
LA JOLLA, Calif.--(BUSINESS WIRE)---- $SBIO #Advacam--Advacam, provider of radiation detectors that map radiation aboard the International Space Station (ISS) and Vector Space Biosciences (crypto symb...
Vector Space Biosciences (SBIO) Is Now Available for Trading on LBank Exchange
Road Town, Virgin Islands--(Newsfile Corp. - September 24, 2023) - LBank Exchange, a global digital asset trading platform, listed Vector Space Biosciences (SBIO) on September 15, 2023. For all users ...